sr 33557 has been researched along with egtazic acid in 1 studies
| Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (egtazic acid) | Trials (egtazic acid) | Recent Studies (post-2010) (egtazic acid) |
|---|---|---|---|---|---|
| 50 | 3 | 1 | 10,021 | 11 | 686 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hata, R; Kato, Y; Kubota, E; Miyazaki, K; Ozawa, S; St-Pierre, Y; Tsukuda, M | 1 |
1 other study(ies) available for sr 33557 and egtazic acid
| Article | Year |
|---|---|
Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Line, Tumor; Chelating Agents; Desipramine; Egtazic Acid; Enzyme Activation; Extracellular Fluid; Hydrogen-Ion Concentration; Indolizines; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Melanoma; Mibefradil; Mice; NF-kappa B; Nimodipine; Perhexiline; Phenethylamines; Phospholipase D; Phosphorylation; Promoter Regions, Genetic; Sphingomyelin Phosphodiesterase | 2007 |